Collecting tissue samples to understand solid tumors better

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to collect cancer and normal tissue specimens from patients diagnosed with solid tumors to analyze them using advanced molecular profiling technologies. By examining these samples, researchers hope to uncover the mechanisms behind cancer cell metastasis and drug resistance, which are not well understood. The study will involve approximately 320,000 patients diagnosed with cancer in the UK each year, focusing on the genetic and molecular factors that contribute to treatment outcomes. Insights gained from this research could lead to the development of improved cancer therapies and predictive tests for treatment tolerance.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Male and female patients over the age of 18 years who have been diagnosed with a solid tumour and who are seen at the Barts Health NHS Trust for clinical management of their tumour.
2. Male or female more than 18 years of age
3. Able to participate in the study.
4. Able to give informed consent.
5. Patients enrolled into other clinical trials may be included into this study

Exclusion Criteria

1. Any co-existing medical condition that in the Investigator's judgement will substantially increase the risk associated with the patient's participation in the study
2. Psychiatric disorders or altered mental status precluding understanding of the informed consent process and/or completion of the necessary studies
3. Physical or mental health issues that preclude them from participation

Where it's running

• St Bartholomew's Hospital
  London, United Kingdom Recruiting

Study contacts

• Study coordinator: Thomas Powles
• Email: bci-orchidtrials@qmul.ac.uk
• Phone: 0207 882 8762

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Testing how well different doses of BI 4060107 are tolerated in adults with unresectable advanced solid tumours

  This trial tests different dose levels of BI 4060107 to see which dose patients with advanced solid tumours can tolerate.

  Recruiting at 3 sites Phase 1 Aimedbio · Irving, Texas and 5 other locations · NCT07827144

• Testing different dose levels of BI 3822971 in adults with advanced solid tumors

  A single-arm early-phase trial is testing how well BI 3822971 is tolerated in adults with advanced or metastatic solid cancers who have exhausted standard therapies.

  Recruiting at 5 sites Phase 1 Boehringer Ingelheim · Leuven and 10 other locations · NCT07744152

• GEN1119 in people with solid tumors

  This phase 1 trial tests GEN1119 in adults with solid cancers to see if it is safe and how it behaves in the body and may show signs of activity against tumors.

  Recruiting at 8 sites Phase 1 Genmab · Rennes, Ille Et Vilaine and 7 other locations · NCT07695831

• AZD4956 alone or with saruparib for advanced HRR-deficient solid tumors

  This will test AZD4956 by itself and together with saruparib in people who have advanced or metastatic solid tumors with homologous recombination repair defects.

  Recruiting at 14 sites Phase 1/2 AstraZeneca · New York, New York and 18 other locations · NCT07446855

• Subcutaneous durvalumab plus hyaluronidase dose-finding and safety for solid tumors

  This study will test whether a subcutaneous (under-the-skin) injection of durvalumab with hyaluronidase gives similar blood levels and is safe for people with certain advanced solid tumors, including unresectable liver cancer and specific forms of lung cancer.

  Recruiting at 14 sites Phase 1 AstraZeneca · Fitzroy and 18 other locations · NCT07391670

• Different doses of BI 3810944 for adults with advanced solid tumors

  This trial tests different doses of the experimental drug BI 3810944 to see if adults with advanced solid tumours, including melanoma, who have not had success with standard treatments can tolerate it and might benefit.

  Recruiting at 5 sites Phase 1 Boehringer Ingelheim · Louisville, Kentucky and 6 other locations · NCT07224425

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.